Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome With Teclistamab Administration : Episode 5
Study Conclusions and Its Implications
Ellen Marin, PA-C, presents the study conclusions and discusses its implications on managing CRS associated with teclistamab with Dr. Lonial.
EP: 1.Overview of Relapsed or Refractory Multiple Myeloma (RRMM)
EP: 2.Overview of Cytokine Release Syndrome (CRS) and Its Management
EP: 3.Background Information and Study Method
EP: 4.Patient Demographics and Study Results
Now Viewing
EP: 5.Study Conclusions and Its Implications
EP: 6.Study Impact and Key Takeaways
Recent Videos
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
Related Content
